TACSTD2 and breast cancer: Treatment with U0126 blocked the increase in pERK1/2 and inhibited TROP2 mediated BC proliferation assessed by CCK-8 assay (Fig. 8b), indicating that pERK1/2 might be involved in the signaling pathway.